It has been identified that HLA-E up-regulation in glioma cells could result in enhanced resistance to NK cell-mediated immune response [27], moreover, the interaction of HLA-E on glioma cells with CD94/NKG2A (a human NK cell inhibitory receptor on lymphocytes) could also compromise innate anti-tumor immune responses [28]. The gene discussed is KLRC1; the disease is glioma.